Research programme: antibody therapies - Daiichi Sankyo/MorphoSys
Alternative Names: HuCAL-derived therapeutic antibodies - Daiichi Sankyo/MorphoSysLatest Information Update: 25 Jul 2024
At a glance
- Originator Daiichi Sankyo Company; MorphoSys
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in Japan (Parenteral)
- 20 May 2009 Preclinical development is ongoing in Japan